A Phase 4 interventional study of Metoprolol and Standard care in Chronic Obstructive Pulmonary Disease, sponsored by Ole Frobert, MD, PhD. Completed at 1 site in Sweden. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Ole Frobert, MD, PhD · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden — 16 open to participants now, 24 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sweden.
Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, this one is the 20th largest by enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2018, is one of 15 in phase 4, and was the 109th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →16 of the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden are open now. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in Sweden, United States, Denmark and 6 more countries
Ages 18–80
Björn Nordlund · Sites in Sweden
Ages 40+
Sanofi · Sites in Sweden, United States, Argentina and 19 more countries
Ages 40–85
Sanofi · Sites in Sweden, United States, Argentina and 22 more countries
Ages 40–80
GlaxoSmithKline · Sites in Sweden, United States, Argentina and 20 more countries
Ages 40–80
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 44 · Phase 4 15
First in 1987; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,713 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 229 across the 123 interventional studies, 470 across the 28 observational. Of the 124 that completed or were terminated, 56 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 152 have an industry lead sponsor. The 10 most frequent:
Ole Frobert, MD, PhD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Ole Frobert, MD, PhD has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
6 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT01460264Region SkaneAn Open Prospective Longitudinal Pulmonary-cardiovascular Cohort Study | 2026-12 |
| NCT05008081Wim JanssensThe CATALINA Study | 2027-03 |
| NCT07573098Björn NordlundDigital Tool for Improved Self-management of COPD | 2027-05-05 |
Add all 6 to your calendar (.ics) → With an account.
Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: In patients with chronic obstructive pulmonary disease (COPD) and concomitant cardiovascular conditions cardio-selective beta-blockers reduce mortality and can be used without significant negative effects on lung function or respiratory symptoms. Observational studies indicate that beta-blocker therapy in COPD even without overt cardiovascular disease, is associated with reduced risk for mortality and COPD exacerbations.
Aim: The overall purpose of our study is to examine the benefit of general beta-blocker therapy on important patient-oriented measures in chronic obstructive pulmonary disease (COPD). Our primary hypothesis that treatment with beta-blockers in patients with COPD and no comorbid heart disease at baseline can prevent a Composite measure of hospitalizations due to cardiovascular diseases, COPD exacerbations and death.
Population: 1700 patients with C OPD. Inclusion criteria are FEV1/FVC \< 70, age >40 years and sinus rhythm 50-120/min. Exclusion criteria include hypersensitivity against metoprolol, atrioventricular (AV) block II or II or sick sinus syndrome without pacemaker, atrial fibrillation or flutter, clinical signs of or previously known cardiovascular disease, systolic blood pressure \< 90, severe asthma, present beta-blocker therapy or ongoing COPD exacerbation.
Intervention: Metoprolol at a target dose of 100 mg in addition to standard COPD care.
Control: No placebo control. Randomized, pragmatic un-blinded controlled study where the control Group receives standard COPD care.
Outcome: The primary outcome is a composite measure of all-cause mortality, C OPD exacerbations, and cardiovascular events after one year. Endpoint data from Swedish national registries and clinical follow-up.
Importance: Beta-blocker treatment to attenuate morbidity in patients with COPD could have great clinical and social importance at a low cost.
Purpose and aims
The overall purpose of our study is to examine the benefit of general beta-blocker therapy on important patient-oriented measures in chronic obstructive pulmonary disease (COPD). Our primary aim is to examine if treatment with beta-blockers in patients with COPD and no comorbid heart disease at baseline can prevent hospitalizations due to cardiovascular diseases, COPD exacerbations and death.
Background
In patients with chronic obstructive pulmonary disease (COPD) and concomitant cardiovascular conditions cardio-selective beta-blockers reduce mortality and can be used without significant negative effects on lung function or respiratory symptoms. Observational studies indicate that beta-blocker therapy in COPD even without overt cardiovascular disease, is associated with reduced risk for mortality and COPD exacerbations.
Research questions
Primary: Does treatment with metoprolol at an aimed dose of 100 mg in addition to standard care statistically significantly decrease the one year rate of a composite measure of death, COPD exacerbations or hospitalization due to a cardiovascular event, in patients with COPD and no cardiovascular disease at baseline? Secondary: Does treatment with metoprolol at an aimed dose of 100 mg in addition to standard care: -decrease the one year rate of a death (all-cause and cause-specific), in patients with COPD and no cardiovascular disease at baseline? -decrease the one year rate of exacerbations, in patients with COPD and no cardiovascular disease at baseline? -decrease the one year rate of hospitalization for myocardial infarction, angina pectoris, heart failure, atrial fibrillation or other forms of arrhythmia, stroke, transient ischemic attack (TIA) or cerebral hemorrhage in patients with COPD and no cardiovascular disease at baseline?
Study design
This is a randomized controlled clinical trial (RCCT) with a pragmatic approach, i.e. a study characterized by a minimized number of inclusion and exclusion criteria, a reduced number of follow-up visits, a reduced complexity at the visits, and an intervention that is additional to standard care but with no placebo control (Figure 1). Invitation letters are sent to all patients, managed at the Department of Respiratory Medicine at Orebro University Hospital or primary health care centers in Region Orebro County, with a doctor´s diagnosis of COPD, no International Classification of Diseases (ICD) codes for cardiovascular diseases and no present beta-blocker therapy.
Inclusion and follow-up will take place at the Clinical Research Support Center in Orebro. In addition, several other Swedish centers for clinical trials have accepted to take part in the study.
The intervention with metoprolol at an aimed dose of 100 mg is prescribed electronically through the ordinary record system, and with financial burdening of the project unless the patient is already part of the high-cost protection for medication. A total of 1700 patients will be randomized to standard care or intervention.
Estimated sample size and statistical power
Sample size is calculated on the basis of: 1) an estimated overall 1-year risk of death of 1% in this mixed cohort of patients with various stages of COPD, 2) a 1-year risk for COPD exacerbations of 20% and 3) a 1-year risk of myocardial infarction, atrial fibrillation, other arrhythmias, heart failure, stroke, TIA or cerebral hemorrhage leading to hospitalization of 2%. The combined 1-year primary endpoint is estimated at 23% (expected survival probability of 0.77) for individuals randomized to usual standard care. With a 5% two-sided alpha level and statistical power set to 80%, 763 patients in each group (total n=1526) is needed to detect a 25% reduction of the primary endpoint in the beta blocker group, corresponding to a hazard ratio of 0.75. In order to control for dropouts and crossing from one group to the other 1700 patients will be included.
Statistical analysis plan
Analysis according to the intention-to-treat principle. Differences between groups in the time-to-event-end points will be assessed using the log-rank test, Kaplan-Meier methodology and Cox proportional hazard model. Differences between study groups will be assessed with unpaired t-tests on original scale or log scale as appropriate. Ordinal variables will be assessed with chi-2 test for trend or Mann-Whitney U test, and Pearson's chi-square test or Fisher's exact test will be used to test differences between proportions. Subgroup analyses will be carried out for patients with a resting heart rate of \<80 vs. ≥80 beats per minute.
Randomization procedure and and study data base
Following written informed consent randomization is performed with a 1:1 allocation using the Smart Trial system web page. A study data base with all patients included in the study will be generated within the Smart-Trial system. The patients' identity will always be confidential.
Monitoring
In accordance with the principles of International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP), monitoring of the study will be arranged by the Sponsor and occur on site before, during and after the trail. During the study, monitors will have regular contacts with the study site to ensure that the study is conducted and documented properly in compliance with the protocol, Standard Operating Procedures (SOPs), ICH-GCP and applicable regulatory requirements.
The number of monitoring visits will occur throughout the trial. The main part of the monitoring will be centralized by regular checks of the data quality in the database. The monitors will review source documents for verification of consistency with the study data recorded in an electronic case report form (eCRF) according to risk based monitoring. Investigators and other responsible personnel must be available during the monitoring visits, possible audits and inspections and should devote sufficient time to these processes.
Ethical considerations
The study will be conducted in accordance with the protocol, applicable regulatory requirements such as and the ethical principles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly in Helsinki, Finland, in 1964 and subsequent versions. The study is approved by the Regional Ethical Review Board of Uppsala, Sweden (DNr 2017-210B) and the Swedish Medical Products Agency (EudraCT no: 2017-001507-76).
Reporting procedures for Adverse Events (AE) and Serious Adverse Events (SAE)
Only AE and SAE that are not considered as signs and symptoms expected and related to the endpoints or known side effects from the study drug will be reported in this study. Events defined as endpoints in the study (e.g. all-cause death, (cardiovascular events requiring hospitalization or COPD exacerbations) will not be reported as AE. This means that other clinical signs and symptoms, which are reported by the patient and observed by the investigator, and in the opinion of the investigator are unexpected in relation to actual diagnosis, will be reported.
Suspected Unexpected Serious Adverse Event (SUSAR) reporting procedure
If the responsible investigator judges the SAE as being drug-related and unexpected (SUSAR) the event must be reported to the sponsor within one working day. SUSARs will be reported using the Council for International Organizations of Medical Sciences (CIOMS) form (http://www.cioms.ch/index.php/cioms-form-i) which will be sent to the Medical Products Agency, since sponsor is not able to report electronically to the EudraVigilance database. The sponsor is responsible for information to all involved investigators in the study.
Annual report
A safety report, including assessment of overall safety and all reported SUSARs will be submitted yearly to the Regulatory Authorities and if requested to the Ethics Committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metoprolol at an aimed dose of 100 mg in addition to usual standard care
Drug: Metoprolol
Usual standard care
Drug: Standard care
Betablocker
Standard care
Also known as: Usual standard care
Mortality, exacerbations and cardiovascular events
A composite measure of all-cause mortality, COPD exacerbations and cardiovascular events after one year
Time frame: One year
Mortality
All-cause mortality after one year
Time frame: One year
Exacerbations
Number of COPD exacerbations after one year
Time frame: One year
Cardiovascular events
Number of cardiovascular events after one year
Time frame: One year
Plan to share: No
Ran from Jun 2018 to primary completion in Dec 2025, 90 months.
Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 90 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metoprolol
Pulmonary Disease, Chronic Obstructive →